EQL Pharma AB (publ) (STO:EQL)
Sweden · Delayed Price · Currency is SEK 85.50
+0.10 (0.12%)
At close: Aug 13, 2025
EQL Pharma AB Company Description
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe.
It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
EQL Pharma AB (publ)
| Country | Sweden |
| Founded | 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Axel Schorling |
Contact Details
Address: Stortorget 1 Lund, 222 23 Sweden | |
| Phone | 46 46 12 01 70 |
| Website | eqlpharma.com |
Stock Details
| Ticker Symbol | EQL |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | April - March |
| Reporting Currency | SEK |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Axel Schorling | President and Chief Executive Officer |
| Christer Fahraeus B.Sc. Maths, h.c., MSc Bio Eng, Ph.D. | Founder and Chairman |
| Anna Jonsson | Chief Financial Officer |
| Martin Kristofferson | Chief Operating Officer |
| Alexander Brising | Chief Commercial Officer |
| Carl Lindgren | Chief Business Development Officer |
| Magnus Erreth | Chief Quality and Supply Chain Officer |